BiomX, Inc. Quarterly report pursuant to Section 13 or 15(d)

Shareholders Equity (Tables)

3 Months Ended

Mar. 31, 2020

	Three months ended March 31,
	2020		2019
Underlying value of ordinary share ($)		6.21		2.03
Exercise price ($)		6.21		2.03
Expected volatility (%)		85.0		93.1
Term of the option (years)		6.25		6.25
Risk-free interest rate (%)		0.52		2.23

	For the three months ended March 31, 2020
	Number of Options			Weighted average exercise price		Aggregate intrinsic value

Outstanding at the beginning of period		3,143,802			1.09		25,733
Granted		814,700			6.21
Forfeited		(16,747	)		1.69
Exercised		(57,325	)		1.85
Outstanding at the end of period		3,884,430			2.87		16,035
Vested at end of period		1,654,090
Weighted average remaining contractual life – years as of March 31, 2020		6.96

Warrant

Issuance Date

Expiration Date

Exercise Price
Per Share

Number of
Shares of
Common Stock
Underlying
Warrants

Private Warrants issued to Yeda (see 1 below)

May 11, 2017

May 11, 2025

)

591,382

Private Warrants issued to Founders (see 2 below)

November 27, 2017

10,589

Private Placement Warrants (see 3 below)

IPO

(December 13, 2018)

December 13, 2023

11.50

2,900,000

Public Warrants (see 4 below)

IPO

(December 13, 2018)

October 28, 2024

11.50

3,500,000

7,001,971

(*)

less than $0.001.